Jan 29, 2026 06:01PM
Jan 29, 2026 06:00PM
Jan 6, 2026 09:00AM
Dec 18, 2025 06:01AM
Dec 18, 2025 06:00AM
Dec 8, 2025 06:00AM
Dec 8, 2025 06:00AM MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Sym
Nov 18, 2025 06:01AM
Nov 18, 2025 06:00AM
Nov 6, 2025 06:00PM
Nov 4, 2025 07:00AM
Oct 30, 2025 07:00PM
Oct 6, 2025 08:00AM
Sep 22, 2025 08:03AM MediciNova completes patient enrollment in ALS drug trial
Sep 22, 2025 08:00AM
Sep 16, 2025 08:00AM
Sep 8, 2025 09:02AM
Sep 8, 2025 09:00AM
Sep 3, 2025 07:00AM
Aug 26, 2025 07:00PM
Jul 31, 2025 07:31PM Medicinova (MNOV) Signs Standby Equity Purchase Agreement for up to $30 Million
Jul 31, 2025 07:30PM
Jul 24, 2025 06:01AM
Jul 24, 2025 06:00AM
Apr 14, 2025 07:00PM
Apr 8, 2025 07:00PM
Dec 5, 2024 06:00PM
Nov 19, 2024 09:02AM Medicinova (MNOV) CEO Issues Letter to Shareholders
Nov 19, 2024 09:00AM
Nov 14, 2024 06:00PM
Nov 11, 2024 06:00PM
Oct 23, 2024 07:00PM
Sep 30, 2024 09:00AM
Sep 9, 2024 07:00PM
Sep 3, 2024 07:00PM MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Mee
Aug 29, 2024 07:00PM
Jun 20, 2024 06:00AM
Jun 5, 2024 06:00AM
Jun 5, 2024 06:00AM
Jun 3, 2024 06:00AM
Jun 3, 2024 06:00AM
May 28, 2024 06:00AM MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Con
May 20, 2024 06:01AM
May 20, 2024 06:00AM
May 14, 2024 06:00AM
May 14, 2024 06:00AM
May 7, 2024 06:01AM
May 7, 2024 06:00AM
Apr 2, 2024 07:00PM MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (20
Mar 26, 2024 07:00PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All